COMPANY

XyloCor Therapeutics Inc.

HQ: Malvern, PA source · xylocor.com ↗ · Mid-Atlantic

Keywords: coronary artery disease cardiovascular gene therapy cardiovascular diseases Refractory Angina Ischemia Angina Refractory Heart Diseases XC001 AdVEGFXC1

Location: Malvern, PA · source · Jan 20, 2021

Profile checked Oct 10, 2026

3Trials (company is sponsor)1NIH grants

Timeline

Aug 27, 2025 Trial start Phase 2: Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG source ↗
Jul 8, 2025 Trial start Phase 2: Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. source ↗
Jan 24, 2020 Trial start Phase 1/Phase 2: Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial) source ↗

Upcoming milestones

Dec 30, 2026 (ESTIMATED) · Phase 2 · Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG · NCT07118449
Jun 30, 2027 (ESTIMATED) · Phase 2 · Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. · NCT07048808

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07048808	Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.	Phase 2	Recruiting	Jul 8, 2025	Jun 30, 2027 (estimated)
NCT07118449	Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG	Phase 2	Not yet recruiting	Aug 27, 2025	Dec 30, 2026 (estimated)
NCT04125732	Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)	Phase 1/Phase 2	Completed	Jan 24, 2020	Jan 31, 2023 (actual)

NIH awards 1

Annual award amounts. Total $300K.

May 25, 2023 NIH award 1R43HL169066-01 FY2023: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI DUCKERS, HENRICUS; recipient as written: XYLOCOR THERAPEUTICS INC, King of Prussia, PA. Combined Pro-Plasticity Reprogr source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗